Loading
institutionsInstitution
University of Malaya Medical Centre
Malaysia's leading academic hospital, with the UM Cancer Research Institute and landmark multi-ethnic breast cancer genetics and outcomes studies.
Also called: UMMCPusat Perubatan Universiti MalayaUM Cancer Research Institute
Overview
The University of Malaya Medical Centre opened in 1968 as the teaching hospital of Malaysia's oldest university and remains its top research hospital. Its oncology programmes include breast surgery and medical oncology, whose Malaysian Breast Cancer Genetic Study with Cancer Research Malaysia (Teo Soo-Hwang) produced the largest Asian breast cancer genetic risk datasets and polygenic risk research; clinical oncology and radiotherapy with early adoption of advanced techniques; haematology and transplant; and colorectal and hepatobiliary surgery. The UM Cancer Research Institute and the Faculty of Medicine's cohort studies inform Malaysia's national cancer control policy and Asian-specific risk models.
Location
Kuala Lumpur, MY
Type
hospital · University of Malaya
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#367 · 18 points (0 Newsweek + 0 NCI + 18 from 9 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to University of Malaya, including child institutions. 335 works · 3,809 citations · 69% open access · 7% clinical trials · 3% reviews.
Oncology works per year
782022
742023
542024
702025
592026
Most works
- Nur Aishah Mohd Taib23 works
- Nirmala Bhoo‐Pathy23 works
- Gwo Fuang Ho21 works
- Cheng Har Yip19 works
- Soo‐Hwang Teo15 works
- Marniza Saad15 works
- Rozita Abdul Malik14 works
- Mee‐Hoong See11 works
- Tania Islam10 works
- Mahmoud Danaee10 works
Most cited
- Breast cancer genetics (Malaysian Breast Cancer Genetic Study)
- Clinical oncology
- Haematology
- UM Cancer Research Institute
Similar pages
- PersonLori J. Pierce
Shares BRCA1 / BRCA2 (HRD), IMRT / IGRT (modern external beam), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonJennifer K. Litton
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- InstitutionLagos University Teaching Hospital
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, IMRT / IGRT (modern external beam), Triple-negative breast cancer (TNBC).
- Key paperFounder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
- Key paperInherited breast cancer in Nigerian women
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
- CompanyOutcomes4Me
Shares Germline (hereditary) testing, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Colorectal cancer.
- Key paperImplementation and audit of mainstream genetic testing within a high-volume UK breast unit for pathogenic variations associated with breast cancer using the R208 and R444.1 National Test Directory criterion
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).